New York, May 21, 2026, 08:08 (EDT)
Vanda Pharmaceuticals VNDA dipped in early premarket trade Thursday, off 0.5% at $6.15 before the bell. Shares closed at $6.18 on Wednesday, when the stock climbed 3.2%. Investors looked at the drugmaker’s latest investor meetings and balanced that with concerns about costs for new product launches.
Vanda is shifting focus from regulatory wins to showing product sales now. The Washington company recently launched Nereus for motion-induced vomiting and Bysanti for schizophrenia and acute bipolar I disorder, putting them in a lineup with Fanapt, Hetlioz and Ponvory.
Thursday is a normal trading day for U.S. markets. According to Nasdaq’s 2026 schedule, the next market holiday is Memorial Day on Monday, May 25. That gives investors two more regular sessions before markets close for the long weekend.
Vanda’s schedule has stayed active but without big headlines. Its investor page showed H.C. Wainwright BioConnect’s fireside chat at Nasdaq set for May 19, with a second stop coming at B. Riley’s investor conference in California on May 20.
Vanda reported first-quarter net product sales up 3% to $51.7 million earlier this month. Fanapt pulled in $29.6 million, up 26%. Hetlioz revenue dropped 24% to $15.9 million. The company’s loss before income taxes widened to $48.4 million. “Strong commercial execution,” president and CEO Mihael H. Polymeropoulos said of the quarter. PR Newswire
The company upped its 2026 revenue target to a range of $240 million to $290 million, up from $230 million to $260 million. Nereus is now expected to add $10 million to $30 million this year. The outlook for Fanapt stays at $150 million to $170 million. Guidance is an estimate by the company, not a promise.
Nereus is grabbing attention among consumers. Reuters said in December that the FDA cleared the drug, making it the first motion-induced vomiting treatment approved in the U.S. in over 40 years. H.C. Wainwright analyst Raghuram Selvaraju has estimated annual U.S. peak sales for that use “could exceed $100 million.” Reuters
Bysanti puts Vanda back in the psychiatry mix, but it’s a packed space. Reuters points out Bristol Myers Squibb’s Cobenfy and Johnson & Johnson’s Caplyta are already on the market with antipsychotics. Jefferies’ Andrew Tsai sees a bigger challenge: Bysanti looks “essentially more or less the same drug” as Fanapt, with matched efficacy and safety. Reuters
But the bear case is straightforward. Launches burn cash, and Vanda spent $50.2 million in operating cash in the first quarter, with a net loss of $48.6 million. If Nereus sees slower demand, Bysanti doesn’t break out from Fanapt, or Hetlioz drops further, the stock’s rebound after approvals may hit a wall on funding or execution.
VNDA is still trading like a small-cap biotech, not a market leader. StockAnalysis puts its market cap at about $372 million and shows a 52-week range between $4.14 and $9.94. That gives the stock space to swing on launch news, analyst calls, or word from a conference.
